Comparative Pharmacology
Head-to-head clinical analysis: DISOMER versus LIVOSTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOMER versus LIVOSTIN.
DISOMER vs LIVOSTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
Adults: 1 mg orally once daily.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
None Documented
None Documented
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Category C
Category C
Antihistamine
Antihistamine